SPORTS randomized controlled trial results
SPORTS is the first investigator-sponsored, core-lab adjudicated, prospective, multi-centre, three-arm RCT comparing outcomes of DES (EluviaTM) vs. BMS (investigator choice) vs. DCB (SeQuent Please), 1:1:1, in TASC C/D lesions.1 Eluvia DES proved statistically superior to BMS in long, complex lesions.
SPORTS RCT met the primary endpoint showing superior percentage diameter stenosis results
Eluvia demonstrated statistically superior performance over BMS, whilst DCB was only non-inferior to BMS when evaluated angiographically for percent diameter stenosis and late lumen loss at 12 months.
1 year angiographic diameter stenosis

Eluvia DES confirmed superior primary patency results over 24 months.*
1 and 2 year primary patency

Late lumen loss and freedom from CD-TLR differed statistically across groups, favoring Eluvia DES
1 and 2 year freedom from CD-TLR

SPORTS randomized controlled trial details
- Results
- Baseline characteristics
| Eluvia DES (n=74) | DCB (n=74) | BMS (n=76) | p-value |
Average diameter stenosis in lesion | 25.3% | 53.7% | 60.0% | <0.0001 |
Average late lumen loss | 0.4mm | 1.1mm | 2.0mm | <0.0001 |
1 Year K-M freedom from CD-TLR | 94.5% | 80.7% | 77.4% | 0.015 |
2 Year K-M freedom from CD-TLR | 85.5% | 75.0% | 63.8% | 0.05 |